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Abstract.  
Aims:  Mitofusin-2 (Mfn2) expression is dysregulated in vascular proliferative disorders 
and its over-expression attenuates the proliferation of vascular smooth muscle cells 
(VSMCs) and neointimal lesion development after balloon angioplasty. We sought to 
gain insight into the mechanisms that control Mfn2 expression in VSMCs. 
Methods and Results: We cloned and characterized 2 kb of the 5'-flanking region of the 
human Mfn2 gene. Its TATA-less promoter contains a CpG island. In keeping with this, 
5’-RACE, revealed 6 transcriptional start sites (TSSs), of which TSS2 and TSS5 were the 
most frequently used. The strong CpG island was found non methylated under conditions 
characterized by large differences in Mfn2 gene expression. The proximal Mfn2 promoter 
contains 6 putative Sp1 motifs. Sp1 binds to the Mfn2 promoter and its over-expression 
activates Mfn2 promoter in VSMCs. Inhibition of Sp1 by WP631 reduced Mfn2 
expression, and Sp1 silencing reduced transcriptional activity of the Mfn2 promoter. In 
keeping with this view,  Sp1 and Mfn2 mRNA levels were down-regulated in aorta early 
after an atherogenic diet in Apolipoprotein E-knockout mice or in VSMCs cultured in the 
presence of low serum.  
Conclusions:  Sp1 is a key factor in maintaining basal Mfn2 transcription in VSMCs. 
Given the anti-proliferative actions of Mfn2, Sp1-induced Mfn2 transcription may 
represent a mechanism for prevention of VSMCs proliferation and neointimal lesion and 
development. 
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Abstract.  
Aims:  Mitofusin-2 (Mfn2) expression is dysregulated in vascular proliferative disorders and 
its over-expression attenuates the proliferation of vascular smooth muscle cells (VSMCs) and 
neointimal lesion development after balloon angioplasty. We sought to gain insight into the 
mechanisms that control Mfn2 expression in VSMCs. 
Methods and Results: We cloned and characterized 2 kb of the 5'-flanking region of the 
human Mfn2 gene. Its TATA-less promoter contains a CpG island. In keeping with this, 5’-
RACE, revealed 6 transcriptional start sites (TSSs), of which TSS2 and TSS5 were the most 
frequently used. The strong CpG island was found non methylated under conditions 
characterized by large differences in Mfn2 gene expression. The proximal Mfn2 promoter 
contains 6 putative Sp1 motifs. Sp1 binds to the Mfn2 promoter and its over-expression 
activates Mfn2 promoter in VSMCs. Inhibition of Sp1 by WP631 reduced Mfn2 expression, 
and Sp1 silencing reduced transcriptional activity of the Mfn2 promoter. In keeping with this 
view,  Sp1 and Mfn2 mRNA levels were down-regulated in aorta early after an atherogenic 
diet in Apolipoprotein E-knockout mice or in VSMCs cultured in the presence of low serum.  
Conclusions:  Sp1 is a key factor in maintaining basal Mfn2 transcription in VSMCs. Given 
the anti-proliferative actions of Mfn2, Sp1-induced Mfn2 transcription may represent a 
mechanism for prevention of VSMCs proliferation and neointimal lesion and development. 
  
 
Keywords:  Vascular smooth muscle cells, mitochondrial dynamics, Mitofusin, Sp1 
transcription factor, vascular proliferative disorders. 
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Introduction. 
Vascular proliferative disorders, such as atherosclerosis, restenosis after balloon 
angioplasty, and vein-graft disease are the most common causes of severe cardiovascular 
disease. Eventually, arterial wall thickening, plaque rupture, and occlusion lead to the clinical 
manifestations of cardiovascular disease (eg, myocardial infarction and stroke), the current 
leading cause of morbimortality in developed countries
1-2
. An important common etiological 
factor in these inflammatory disorders is the development of neointimal lesions caused by the 
accumulation of circulating leukocytes, vascular smooth muscle cells (VSMCs), and non-
cellular material (eg., circulating lipoproteins, extracellular matrix components). Under 
normal conditions, VSMCs residing within the arterial tunica media display a so-called 
'contractile' phenotype characterized by low proliferative and migratory activity and 
expression of differentiation markers (eg., contractile proteins). However, unlike terminally 
differentiated striated muscle cells, VSMCs can revert to a 'synthetic' phenotype featuring 
suppression of differentiation marker gene expression, abundant synthesis of extracellular 
matrix components, and high proliferative and migratory activity
3
. These pathological 
processes are induced by a variety of pathological stimuli, such as atherogenic stimuli, 
mechanical stress of the vessel wall, and vessel denudation
2
. Thus, VSMCs phenotypic 
switching, hyperproliferation and migration into the neointimal layer of the arterial wall are 
essential components of neointimal lesion development. 
Multiple signalling pathways and molecular networks appear to control VSMCs 
growth in response to pathological insults
4-5
. Recently, it has been reported that the 
mitofusin-2 (Mfn2) gene, also named hyperplasia suppressor gene (HSG), encodes a protein 
whose dysregulation is involved in vascular proliferative disorders
6
. This conclusion is based 
on a variety of observations, namely: a) Mfn2 expression is down-regulated in hyper-
proliferative VSMCs from spontaneously hypertensive rat arteries, balloon-injured Wistar 
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Kyoto rat arteries and apolipoprotein E-knock-out (Apo E-KO) mouse atherosclerotic 
arteries; and b) adenoviral-mediated over-expression of Mfn2 suppresses serum-dependent 
proliferation of cultured VSMCs, and attenuates balloon injury-induced neointimal VSMC 
growth and vascular occlusive lesion development in rat carotid arteries. Nevertheless, the 
functional role of Mfn2 is complex and not limited to the regulation of cell proliferation. 
Mfn2 is a mitochondrial outer membrane protein that primarily participates in mitochondrial 
fusion
7
, activates mitochondrial metabolism in mammalian cells
8-9
, and protects against 
apoptosis
10
. Recently, it has been reported that Mfn2 is enriched at the endoplasmic 
reticulum-mitochondria interface, and that Mfn2 in the endoplasmic reticulum is required for 
efficient mitochondrial Ca
2+
 uptake and normal ER morphology. This gene is essential in 
rodents, as mice
 
deficient in Mfn2 die in midgestation, probably
 
because of impaired placental 
function caused by a marked reduction
 
in the number of polyploid giant cells of the placental 
trophoblast
11
. Studies in conditional knockout mice indicate that Mfn2 is required for proper 
development and maintenance of the cerebellum, and that Purkinje cells require Mfn2 for 
their extensive dendritic outgrowth and survival. In humans, Mfn2 mutations cause Charcot–
Marie–Tooth type 2A12, an autosomal dominant neuropathy. In addition, skeletal muscle 
Mfn2 is deficient in human obesity and in type 2 diabetes, which suggests that this gene may 
be involved in the pathophysiology of these metabolic diseases
8
. On the basis of these 
observations, the present study was designed to ascertain the mechanisms that regulate Mfn2 
transcription by investigating the promoter region of human Mfn2.  
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Methods. 
Cloning of human Mfn2 promoter. A human Mfn2 promoter fragment containing positions 
-1982 to +45 from the transcription start site was prepared by PCR amplification using 
human genomic DNA templates, and the following primers: 5’-
cccgggaggcagaggttgtagtgagttgag-3’ and 5’-gaggcgggaggagggaagtggata-3’. The amplified 
DNA fragment was digested with SacI and SmaI and cloned into the SacI/SmaI sites of 
pGL3-promoterless vector (Promega). 
 
Databases and computer analysis. Potential transcription factor-binding sites were mapped 
to the Mfn2 promoter using AliBaba (http://www.alibaba2.com) and TESS 
(http://www.cbil.upenn.edu/tess/) software. CpG islands were located using the CpGPlot 
program (http://www.ebi.ac.uk/emboss/cpgplot/).  
 
Cell culture. Primary rat aorta VSMCs, C3H10T1/2 cells, and the L6E9 rat skeletal muscle 
cell line were used. Primary rat aorta VSMCs were prepared as previously described
13
. Aorta 
were collected from adult male Wistar rats euthanized in a CO2 chamber followed by cervical 
dislocation. Arteries were dissected free from surrounding tissue and adventitia and cut into 
small pieces. Aortic tissue was digested with collagenase (2 mg/ml, Worthington). VSMC 
cells were grown in DMEM-F12 (1:1) supplemented with 10% FBS, 2 mM glutamine, 0.25 
μg/ml fungizone, 100 units/ml penicillin and 100 μg/ml streptomycin and 25 mM Hepes. See 
details in Supplementary Methods. 
 
In vivo studies. Apo E-KO mice (C57BL/6J, Charles River) were fed either control chow or 
an atherogenic diet for 1 week. Mice were euthanized and aortas were removed, and 
immediately snap-frozen. Adult male Wistar rats were euthanized and tissues removed and 
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frozen. Euthanasia of the animals was performed in a CO2 chamber followed by cervical 
dislocation. Euthanasia was confirmed by checking for lack of response to limb and tail 
pinch. All experiments were conducted in accordance with approved institutional operating 
protocols and the Directive 2010/63/EU of the European Parliament. See details in 
Supplementary Methods. 
 
Rapid amplification of cDNA ends (RACE). The TSSs of human Mfn2 in skeletal muscle 
were identified using the FirstChoice
®
 RACE-Ready cDNA (Ambion) following the 
manufacturer’s protocol. See details in Supplementary Methods.  
 
Construction of luciferase reporter vectors. The pGL3-promoterless vector was generated 
by excision of the SV40 promoter by digestion with BglIII/HindIII. The -1982/+45 Mfn2 
promoter fragment was cloned into the SacI/SmaI sites of pGL3-promoterless vector 
(Promega). The subsequent 5’ deletion constructs were produced by  digestion and religation. 
See details in Supplementary Methods. 
 
Transfection and luciferase assays. VSMCs, C3H10T1/2 or L6E9 cells were seeded at a 
density of 25,000 cells per well, 24 hours before transfection. pGL3 reporter constructs (250 
ng) and 20 ng of Renilla luciferase were transfected using FuGENE 6.  At 40 hours post-
transfeccion, luciferase and Renilla activity was measured using the Dual Luciferase Reporter 
Assay System (Promega). See details  in Supplementary Methods.  
 
Site-Directed Mutagenesis. A QuikChange
®
 Site-Directed Mutagenesis Kit (Stratagene) was 
used to introduce mutations into two putative Inr sites (mutI2: 5’- 
agtcgcggggcagcGgCcgcgtaaggagtaggcg-3’; mutI5: 5’- 
 8 
acccgggtcgaggCgGCCGctgaggcgactggtgacg-3’; mutations are in capitals), following the 
manufacturer’s protocol.  
 
Bisulfite modification of genomic DNA, PCR and sequencing. Evaluation of CpG 
methylation status of the samples was performed by bisulfite sequencing. Genomic DNA 
from different sources was modified with the EzWay DNA Methylation Detection Kit (Koma 
Biotech) according to manufacturer’s protocol. Modified gDNA was used to PCR-amplify a 
519 bp region spanning from -489 to +29 of the Mfn2 gene, and sequenced.  See further 
details in Supplementary Methods. 
 
RNA purification and measurement of mRNA expression. Total RNA was purified using 
TRIZOL Reagent (GibcoBRL, Invitrogen) and mRNA expression was determined by real 
time-PCR, as described in Supplementary Methods.  
 
Chromatin immunoprecipitation. Chromatin was isolated from rat L6E9 cells and VSMCs. 
Cells were cross-linked using a final concentration of 1% formaldehyde for 10 min. The 
cross-linking reaction was stopped by the addition of 1.25 M glycine. Cross-linked cells were 
washed, collected, and lysed. Nuclei were then lysed in 50 mM Tris-HCl (pH 8.1), 10 mM 
EDTA, 1% SDS and protease inhibitor cocktail (Roche). Isolated chromatin was then 
sonicated to an average fragment size of 400 to 500 bp. Precleared chromatin was then 
immunoprecipitated with antibody against Sp1 (sc-59 X, Santa Cruz Biotech) and pre-
blocked Protein A beads (Sigma). See further details in Supplementary methods. 
 
Statistical analysis. Results represent the mean±S.E.M. of 3-5 experiments. Statistical 
differences were evaluated using Student’s t-test or ANOVA and further post-hoc t-test. 
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Results. 
 
The Mfn2 gene contains a CpG island that is non-methylated under conditions characterized 
by large differences in Mfn2 expression. 
The human Mfn2 gene is located in locus 1p36.22 on chromosome 1. Mfn2 has 19 exons and 
translation starts in exon 3.  In silico analysis of the 5’-flanking region of human Mfn2 
identified putative binding sites for several transcription factors, including C/EBP and 
GATA-1, which may mediate tissue-specific expression of Mfn2, and stress-response factors 
such as NFκB and AP-1 (Figure 1A). Estrogen-related receptor-α (ERRα)-binding element, 
which is required for PGC-1 and PGC-1 stimulation of Mfn2 promoter is also shown14-15. 
The region near exon 1 is TATA-less, but it contains a G/C-rich region bearing several 
potential Sp1-binding motifs (Figure 1A). The mouse (Figure 1B) and rat (Supplementary 
Figure 1) Mfn2 promoters showed a high identity to the human promoter and also contained 
putative binding sites for ERR-α, C/EBP, GATA-1, NFκB, AP-1 and Sp1 transcription 
factors. 
CpG islands are defined as sequences larger than 200 bp with a proportion of C+G 
greater than 50% and with a CpG observed/CpG expected ratio of 0.6 or higher
16
. Using the 
CpGPlot program, analysis of the human Mfn2 promoter region from -600 to +600 (relative 
to the transcription initiation site) revealed a CpG island that lies between -266 and +362 
(Supplementary Figure 2). A CpG island was also detected in the mouse Mfn2 promoter 
between -316 and +225, and rat Mfn2 promoter between -278 and +113 (data not shown). 
Based on the CpG ratio, GC content and length of the CpG-rich region, the Mfn2 promoter is 
defined as a High-CpG promoter (HCP) that represents a strong CpG island
17
. 
In vertebrates, CpG islands are predominantly non-methylated
18
. Non-methylated 
CpG islands are organized in a characteristic chromatin structure that predisposes them 
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toward promoter activity. As Mfn2 expression has been shown to be ubiquitous, we 
hypothesized that Mfn2 promoter CpG island should be in a non-methylated state in vivo. To 
this end, we selected cells or tissues with different expression levels of  Mfn2. This included 
VSMCs or skeletal muscle cells (L6E9) before and after differentiation (Figure 2A and data 
not shown), rat INS-1 insulinoma, rat H4IIE hepatoma or rat FAO hepatoma tumoral cell 
lines (Figure 2B) or different rat tissues (Figure 2C). Proliferating VSMCs and L6E9 
myoblasts showed a low Mfn2 expression compared to differentiated cells (Figure 2A and 
data not shown), and tissues or rat tumour cells showed variable expression levels of Mfn2 
(Figures 2B and 2C). The bisulfite genomic DNA sequencing technique was used to 
determine the DNA methylation status of a fragment of rat Mfn2 promoter region (-262 to -
52), containing 15 individual CpG sites (Figure 2D). Sequencing data evidenced the absence 
of methylation in any CpG site, regardless of the cell or tissue analyzed. As an example we 
show a 41 pb gDNA fragment (-107 to –67) of rat Mfn2 promoter region containing 4 CpG 
sites (Figure 2E, first sequence), the same sequence after bisulfite treatment (Figure 2E, 
second sequence), and the sequencing result of not differentiated VSMCs (Figure 2E, first 
electrospherogram). The methylation control showed protection against bisulfite treatment for 
all cytosine residues analyzed (Figure 2E, second electrospherogram). Thus, our results 
indicate the absence of in vivo methylation in the rat Mfn2 promoter.  
 
Mfn2 shows multiple transcription start sites. 
   TATA-less promoters that contain CpG islands usually initiate transcription from multiple 
weak start sites, which are often distributed over a region of about 100 bp
19. 5’-RACE was 
performed to determine whether transcription start sites (TSSs) other than those found in the 
GeneBank and localized at +1 and +142. We used a commercial 5’-RACE-ready kit with an 
adapter linked only to mRNA with CAP (from human skeletal muscle) to avoid the 
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amplification of partially degraded mRNA, and nested primers located in exon 2. Several 
bands were detected after 5’-RACE (Supplementary Figure 3A), which were cloned in the T-
A cloning vector pGEM-T. The sequence of 22 randomly selected clones revealed two 
predominant TSSs, one in a narrow window between -7 and -4 (8 clones; TSS2) and another 
at position +58 (8 clones; TSS5) (Supplementary Figure 3B). Additional TSSs were detected 
at -47 (2 clones; TSS1), +37 (1 clone; TSS3), +52 (2 clones; TSS4) and +124 (1 clone; TSS6) 
(Supplementary Figure 3B). Three of these start sites showed homology with Inr motifs. 
Transcription in Inr core promoters can initiate in a single site or in a cluster of multiple sites 
in the vicinity of Inr, and not necessarily at A+1 position, which seems to be the case of 
TSS2
20
. It is likely that the TSS localized at +142 according to GeneBank corresponds to an 
incomplete sequence. To examine the role of the most prevalent TSS of human Mfn2, we 
cloned the Mfn2 fragment -229/+348 into a luciferase reporter plasmid and performed 5' 
deletions. In transiently transfected 10T1/2 cells, the construct -229/+348-Luc exhibited 200-
fold greater luciferase activity than the promoter-less construct, and 5' deletions up to +84 
produced a progressive loss in promoter activity (~70-fold greater activity than the promoter-
less construct) (Figure 3A). Construct +123/+348-Luc did not show significant differences in 
luciferase activity compared to the promoterless vector (Figure 3A). Although the +123/+348 
Mfn2 fragment maintained the TSS6, its loss of promoter activity may be attributable to the 
lack of 5’ sequences required for the positioning of basal transcription machinery. Given that 
TSS2 and TSS5 are the two most represented TSSs found by RACE analysis, we next 
examined their relevance for Mfn2 promoter activity. To this end, the related Inr elements in 
TSS2 and TSS5 in -229/+348-luc were subjected to mutagenesis by substituting the A+1 and 
the base at position +3 by G and C, respectively, which greatly reduces Inr activity both in 
vitro and in vivo
21
. As commonly found in other CpG island-containing promoters(18), single 
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TSS2 or TSS5 mutations did not modify the activity of the -229/+348 promoter in transient 
transfection assays, but double mutants showed a 50% reduction in this activity (Figure 3B).  
 
Identification of the core promoter of human Mfn2. 
Next, we aimed to identify the functionally relevant cis-regulatory elements in the 
human Mfn2 promoter. Several fragments spanning from -1982 to +45 and -54 to +45 (all 
containing TSS1, TSS2 and TSS3) were cloned in a luciferase reporter vector and the 
resulting constructs were transiently transfected in rat VSMCs or in murine 10T1/2 cells, 
which show endogenous expression of Mfn2
8-9
. The -1982/+45-Luc construct showed 25% 
stronger promoter activity than the viral SV40 promoter when transfected in 10T1/2 cells 
(data not shown). In VSMCs and 10T1/2 cells, 5’ deletion from -1332 to -532 caused a 
marked increase in promoter activity, suggesting that repressor factors may negatively 
regulate Mfn2 expression in these cells by binding to sequences within -1332/-532 (Figure 
4A). Furthermore, deletion of the region between -229 to -54 markedly reduced promoter 
activity in VSMCs and 10T1/2 cells (Figure 4A). Elimination of this region, while 
maintaining upstream and downstream sequences, also caused an 80% reduction in the 
promoter activity in 10T1/2 cells (Figure 4B). Altogether, our data indicate that the region -
229/-54 is critical for maintaining high transcriptional activity of the human Mfn2 promoter 
in VSMCs and fibroblasts. 
 
Regulatory role of Sp1. 
The -229/-54 region of the Mfn2 promoter is a GC-rich region with multiple 
consensus binding sites for Sp1 (Figure 1). It has been suggested that in promoters contained 
within CpG islands, Sp1 would direct the basal transcriptional machinery to form a pre-
initiation complex within a loosely defined window(18). To examine whether Mfn2 promoter 
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activity is affected by the Sp1, we performed transient transfection experiments with the -
1984/+45-pGL3 construct and expression vectors encoding Sp1. In 10T1/2 cells, Sp1 induced 
a 3-fold increase in luciferase activity (Figure 5A). In VSMCs, Sp1 also enhanced the 
promoter activity (4.5-fold) (Figure 5A).  
In order to assess Sp1 binding to Mfn2 promoter, chromatin immunoprecipitation 
(ChIP) assays were performed. Endogenous chromatin of primary rat VSMCs or L6E9 
muscle cell cultures was immunoprecipitated with or without anti-Sp1 antibodies. The 
precipitated genomic DNA was then analyzed by PCR using the primers encompassing the 
Sp1-binding site in the Mfn2 promoter. Chromatin fragments containing the Sp1 DNA 
binding site from the Mfn2 promoter region were specifically immunoprecipitated by anti-
Sp1 antibody (Figure 5B) showing specific amplification band for both VSMCs and L6E9 
cells. No chromatin fragments were immunoprecipitated in the absence of antibody (Figure 
5B). Binding of Sp1 to the promoter region of Mfn2 was specific, as no chromatin fragments 
in the coding region of Mfn2 (exon 2) or in the intergenic region ~10 kb upstream of the 
Mfn2 transcription start site were immunoprecipitated with the anti-Sp1 antibody (Figure 5B). 
Thus, endogenous Sp1 binds to Mfn2 promoter in primary VSMCs and L6E9 cells. 
Considering that Sp1 binds to Mfn2 promoter and increases Mfn2 promoter activity in 
cell cultures, we wanted to assess if this effect/phenotype was also present in a more 
physiological in vivo model. Consistent with previous studies showing reduced Mfn2 
expression in arteries from Apolipoprotein E-null mice (ApoE-KO) subjected to a high-fat 
diet (6), we found a marked reduction in Sp1 mRNA levels in aorta from Apo E-KO mice fed 
an atherogenic diet for 1 week (50% decrease versus control diet) (Figure 5C, left panel). 
Under these conditions, Mfn2 mRNA levels also underwent a significant reduction (60% 
decrease) (Figure 5C, right panel). The effects of an atherogenic diet were transient and no 
effects on Sp1 or Mfn2 gene expression were detected in aorta after more prolonged treatment 
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(2 months) (data not shown). These data suggest that downregulation of Sp1 at the onset of 
atherosclerosis contributes to reduced Mfn2 transcription in aortic tissue. A similar co-
regulation of Sp1 and Mfn2  was detected upon culturing VSMCs in normal (10% FBS) or 
low serum (0.2% during 48h) conditions. Total RNA was obtained and real-time PCR assays 
were performed. Sp1 gene expression was lower in VSMCs cultured in 0.2% FBS than in the 
normal serum condition (Figure 5D, left panel). Accordingly, Mfn2 mRNA levels were also 
downregulated in this situation (Figure 5D, right panel).   
Searching for the in vivo effects of Sp1 depletion on Mfn2 protein expression, a 
shRNA approach was used. In order to knock down Sp1 expression, we infected VSMCs and 
L6E9 cultures with lentivirus encoding specific Sp1 shRNA (shSp1) or scramble control 
sequences (C). Western blot analysis revealed an almost total depletion of Sp1 protein in 
shSp1 transduced VSMCs and an 85% downregulation in shSp1 transduced L6E9 cells 
(Figure 6A and B).  
In order to evaluate the impact of Sp1 loss-of-function on Mfn2 promoter activity 
control and Sp1 depleted  cells were transfected with the -532/+45-pGL3 or -229/-54-pGL3 
and promoter activity was tested. As expected, the luciferase assay showed a significant 
decrease in promoter activity in Sp1 knock-down cells compared to controls (Figure 6C), The 
construct containing the -1984/+45 promoter region showed the same result (data not shown). 
Thus, these data confirms the essential role of Sp1 in Mfn2 promoter activation.  
Sp1 consensus binding sites are target for specific inhibitors. Thus, next we examined 
the role of Sp1 in the control of Mfn2 gene expression, by using WP631, a specific inhibitor 
of Sp1
22-23
. For this purpose, L6E9 cells transfected with -532/+45-pGL3 or -229/-54-pGL3 
constructs were incubated in the presence of 300 nM WP631 during 24h. As shown in Figure 
6D, WP631 caused a 90% inhibition in luciferase activity for both constructs.  In order to 
further assay WP631 action, we incubated primary rat VSMCs with the compound and 
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analyzed Mfn2 transcript expression. Incubation of VSMCs with different nanomolar 
concentrations of WP631 for 24 hours caused a significant reduction of Mfn2 mRNA levels 
(Figure 6E). In addition, incubation with WP631 markedly reduced Mfn2 mRNA levels in 
MCF-7/VP cells (data not shown), in agreement with a direct effect of WP631 on Sp1-
regulated Mfn2 transcription. 
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Discussion. 
 
In the present study, we have both identified and characterized the promoter regions 
of human, mouse and rat Mfn2 genes. These promoters contain a region of approximately 500 
bp which satisfies the criteria for the presence of a strong CpG island(15, 16). Under in vivo 
conditions no evidence for methylation has been found, which is in agreement with data 
indicating that strong CpG islands-containing promoter are not methylated
17, 24
. We have also 
shown that the human Mfn2 promoter is TATA-less and that the -229/+123 region, which 
contains 6 putative binding sites for the transcription factor Sp1, is essential for normal 
transcriptional activity. In keeping with the above, human Mfn2 shows 6 transcriptional start 
sites. The functional relevance of Sp1 transcription factor in the control of Mfn2 expression is 
suggested by the following findings: a) Sp1 over-expression enhances the transcriptional 
activity of the Mfn2 promoter, b) Sp1 ablation down-regulates Mfn2 promoter activity in 
VSMCs and L6E9 cells; c) the stimulatory effect of Sp1 on Mfn2 promoter activity is 
abolished  pharmacologically by using the specific Sp1 inhibitor WP631, d) Sp1 binds in vivo 
to the Mfn2 promoter; and e) Apo E-KO mice subjected to an atherogenic diet undergo a 
concomitant reduction in Mfn2 and Sp1 mRNA levels in aorta. Altogether, our data 
demonstrate that the human Mfn2 promoter belongs to the class of CpG dispersed 
promoters
25
, in which methylation is prevented under in vivo conditions and in which 
transcription is driven and regulated by Sp1.  
The Mfn2 promoter represents a model to understand the elements responsible for the 
core promoter function of promoters located in CpG islands. This aspect is particularly 
relevant since the specific mechanisms that control the activity of promoters located in CpG 
islands are not well understood
19
 in spite of the fact that almost 60% of the promoter regions 
of human genes are located within these islands
26. Using 5’-RACE, we found that 
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transcription of Mfn2 in human skeletal muscle can be initiated in at least 6 TSS, which show 
homology with Inr elements, a common feature of promoters in CpG islands
19
. The two main 
transcriptional start points identified by sequencing of 5’-RACE products, TSS2 and TSS5, 
were mutated to examine their functional importance. Individually, mutation did not change 
the strength of the promoter although the double mutant reduced promoter activity by 50%. 
These results indicate that the human Mfn2 gene constitutes a redundant system capable of 
maintaining high promoter activity even after mutation of the most frequently used individual 
TSSs. In addition, our data demonstrate the presence of 5’ heterogeneity of the Mfn2 
transcripts of human origin, which may have an impact on the biological activities of the 
products of this gene. 
DNA methylation involves the addition of methyl groups to cytosine located 5’ to 
guanine in CpG nucleotide pairs, and methyl-CpG is now recognized as a gene-silencing 
signal
27-28
. In healthy adult tissue, strong CpG islands are usually unmethylated. Thus, de 
novo methylation depends on the local CpG density, making it more likely for weak CpG 
islands
17
. In agreement with these observations, we found no methylation of the Mfn2 
promoter in cultured cells from tumor origin, adult rat tissues or rat VSMCs or skeletal 
muscle cells before and after differentiation. However, methylation of human Mfn2 is 
undertaken in vitro by HpaII or SssI methylases (data not shown), which suggests that under 
in vivo conditions different factors may cause steric hindrance and prevent methylation. The 
fact that we did not found any tissue or cell type in which Mfn2 expression was completely 
absent points to the essentiality of  Mfn2 function in cells. Thus, the demethylated CpG island 
status and the concomitant open chromatin structure of the promoter seem to be necessary to 
guarantee at least a minimal Mfn2 promoter activity/Mfn2 expression. Whether other 
pathological conditions cause methylation of the Mfn2 promoter remains to be elucidated. 
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We have identified cis-regulatory elements and transcription factors involved in the 
regulation of human Mfn2 promoter activity. In the cell types tested (rat VSMCs, and murine 
10T1/2 fibroblasts), deletion of the -1332/-532 region enhanced promoter activity, thereby 
providing evidence for the operation of repressor factors. In addition, deletion of the -229/-54 
region suppressed promoter activity, thereby providing evidence that this is a critical region 
of the core Mfn2 promoter. Consistent with the observation that the presence of several 
putative Sp1-binding sites is a common feature of CpG islands
19
, computer-assisted sequence 
analysis of the human Mfn2 promoter revealed 6 potential consensus sequences for the Sp1 
family of transcription factors in the -229/-54 region. Importantly, Sp1 overexpression 
increased Mfn2 promoter transcription in fibroblasts and VSMCs, and this activation was 
abolished by in vitro promoter methylation. In addition, Sp1 binding to Mfn2 promoter was 
confirmed for VSMCs and L6E9 cells, suggesting that its function as a transcriptional 
activator on Mfn2 is not restricted to a specific cell type. 
Further in vivo evidence demonstrated that in aortas from Apo-E –KO mice subjected 
to a high-fat diet, Sp1 as well as Mfn2 expression were decreased. The effects of an 
atherogenic diet were transient and no effects on Sp1 or Mfn2 gene expression were detected 
in aorta after more prolonged treatment (2 months). The transient repression of  Mfn2 
detected  early after the implementation of an atherogenic diet is similar to the transient 
repression of Mfn2 detected in carotid arteries after a mechanical injury induced by 
angioplasty
6
. In keeping with the observations in aorta, VSMCs showed a parallel reduction 
in Sp1 and Mfn2 mRNA expression levels when grown in low serum conditions. In addition, 
Sp1 inhibition caused Mfn2 gene repression in VSMCs. Therefore, our studies provide solid 
evidence that Sp1 binds to Mfn2 promoter and regulates Mfn2 expression in several in vivo 
systems. 
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In conclusion, Sp1 binds to the Mfn2 promoter in different cells types, which includes 
VSMCs and skeletal muscle cells, and  transactivates the basal machinery of  Mfn2. Sp1 has 
been reported to inhibit VSMCs proliferation by induction of p27 and by repression of p21 
expression and cyclin D1-Cdk4-p21 complex formation
29-30
. In this study we provide 
evidence for a stimulatory role of Sp1 on Mfn2 expression in VSMCs. Based on the 
antiproliferative action of Mfn2 in VSMCs, our data reveal a new mechanism by which Sp1 
may prevent the development of vascular proliferative disease. 
 
Funding. 
This work was supported by research grants from the Ministerio de Ciencia e Innovación 
(MICINN) (SAF2005-0445, SAF2008-03803), the Fondo de Investigaciones Sanitarias 
(PI041123, PI050317, RECAVA: RD06/0014/0021), grant 2005SGR00947 from the 
Generalitat de Catalunya, and CIBERDEM (“Instituto de Salud Carlos III”). A.Z. was a 
recipient of a Science Intensification Award from the University of Barcelona (UB). F.X.S. 
was a recipient of predoctoral fellowships from the Danone Foundation and from UB. D.N. 
was the recipient of a predoctoral fellowship from the MICINN, Spain. M.V.-C was the 
recipient of a predoctoral fellowship from Generalitat Valenciana and from Danone 
Foundation. H.G.-N. received salary support from CSIC’s JAE-Doctor programme. 
 
Acknowledgments. 
We thank Tanya Yates for her editorial support.  
 
Conflict of Interest. 
No conflict of interests are disclosed by the authors.
 20 
 
References. 
1. Mathieu P, Lemieux I, Despres JP. Obesity, inflammation, and cardiovascular risk. 
Clin Pharmacol Ther 2010;87:407-416. 
2. Libby P, Tanaka H. The molecular bases of restenosis. ProgCardiovascDis 
1997;40:97-106. 
3. Kawai-Kowase K, Owens GK. Multiple repressor pathways contribute to phenotypic 
switching of vascular smooth muscle cells. AmJPhysiol Cell Physiol 2007;292:C59-
C69. 
4. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic 
target for vascular proliferative disease. Circulation 1998;98:82-89. 
5. Andres V. Control of vascular cell proliferation and migration by cyclin-dependent 
kinase signalling: new perspectives and therapeutic potential. CardiovascRes 
2004;63:11-21. 
6. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, et al. Dysregulation of HSG triggers 
vascular proliferative disorders. NatCell Biol 2004;6:872-883. 
7. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. 
JCell Sci 2001;114:867-874. 
8. Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, et al. Mitofusin-2 
determines mitochondrial network architecture and mitochondrial metabolism. A 
novel regulatory mechanism altered in obesity. JBiolChem 2003;278:17190-17197. 
9. Pich S, Bach D, Briones P, Liesa M, Camps M, Testar X, et al. The Charcot-Marie-
Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of 
OXPHOS system. Human Molecular Genetics 2005. 
10. Neuspiel M, Zunino R, Gangaraju S, Rippstein P, McBride H. Activated mitofusin 2 
signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility 
to radical induced depolarization. JBiolChem 2005;280:25060-25070. 
11. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 
and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic 
development. JCell Biol 2003;160:189-200. 
12. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et 
al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth 
neuropathy type 2A. NatGenet 2004;36:449-451. 
13. Castro C, Diez-Juan A, Cortes MJ, Andres V. Distinct regulation of mitogen-activated 
protein kinases and p27Kip1 in smooth muscle cells from different vascular beds. A 
potential role in establishing regional phenotypic variance. JBiolChem 
2003;278:4482-4490. 
14. Liesa M, Borda-d'+•gua B, Medina-G+Ýmez G, Lelliott CJ, Paz JrC, Rojo M, et al. 
Mitochondrial Fusion Is Increased by the Nuclear Coactivator PGC-1+Ý. PLoS ONE 
2008;3:e3613. 
15. Soriano FX, Liesa M, Bach D, Chan DC, Palacin M, Zorzano A. Evidence for a 
mitochondrial regulatory pathway defined by peroxisome proliferator-activated 
receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2. 
Diabetes 2006;55:1783-1791. 
16. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. JMolBiol 
1987;196:261-282. 
 21 
17. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, et al. Distribution, 
silencing potential and evolutionary impact of promoter DNA methylation in the 
human genome. Nat Genet 2007;39:457-466. 
18. Deaton AeM, Bird A. CpG islands and the regulation of transcription. Genes & 
Development 2011;25:1010-1022. 
19. Smale ST, Kadonaga JT. The RNA polymerase II core promoter. AnnuRevBiochem 
2003;72:449-479. 
20. Butler JE, Kadonaga JT. The RNA polymerase II core promoter: a key component in 
the regulation of gene expression. Genes Dev 2002;16:2583-2592. 
21. Lo K, Smale ST. Generality of a functional initiator consensus sequence. Gene 
1996;182:13-22. 
22. Martin B, Vaquero A, Priebe W, Portugal J. Bisanthracycline WP631 inhibits basal 
and Sp1-activated transcription initiation in vitro. Nucleic Acids Res 1999;27:3402-
3409. 
23. Mansilla S, Priebe W, Portugal J. Sp1-targeted inhibition of gene transcription by 
WP631 in transfected lymphocytes. Biochemistry 2004;43:7584-7592. 
24. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, et al. DNA 
methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006;38:1378-
1385. 
25. Juven-Gershon T, Hsu JY, Theisen JW, Kadonaga JT. The RNA polymerase II core 
promoter - the gateway to transcription. Curr Opin Cell Biol 2008;20:253-259. 
26. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. 
ProcNatlAcadSciUSA 1993;90:11995-11999. 
27. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21. 
28. Feil R, Khosla S. Genomic imprinting in mammals: an interplay between chromatin 
and DNA methylation? Trends Genet 1999;15:431-435. 
29. Kavurma MM, Khachigian LM. Sp1 inhibits proliferation and induces apoptosis in 
vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin 
D1-Cdk4-p21WAF1/Cip1 complex formation. JBiolChem 2003;278:32537-32543. 
30. Andres V, Urena J, Poch E, Chen D, Goukassian D. Role of Sp1 in the induction of 
p27 gene expression in vascular smooth muscle cells in vitro and after balloon 
angioplasty. ArteriosclerThrombVascBiol 2001;21:342-347. 
 
 
 22 
Figure Legends. 
 
Figure 1. Nucleotide sequence of the 5’ region of human (panel A) and mouse (panel B) 
Mfn2.  
+1 indicates the transcription start site reported in NCBI for human Mfn2 (NM 014874.2) and 
the homologous site for mouse Mfn2 (NP 573464). The first exon is shaded. Putative 
transcription-regulatory motifs are in bold and underlined. Functional estrogen-related 
receptor-α (ERRα)-binding element is shown inside a rectangle. 
 
Figure 2. Lack of methylation of the 5´-flanking region of human Mfn2. 
A) Left: Western blot showing the expression of SMα-actin and the constitutive protein 
ERK2 in differentiated (D) and not differentiated (ND) VSMCs. Right: Mfn2 and Acidic 
Ribosomal Protein (ARP) mRNA levels from differentiated and not differentiated VSMCs 
were measured by real time-PCR. (Mean ± S.E.M., * p<0.01) 
B) and C) Mfn2 and Acidic Ribosomal Protein (ARP) mRNA levels from INS-1, H4IIE and 
FAO cell lines, and  from lung, testis, kidney and heart from adult rat, and aorta from young 
and old rat were measured by real time-PCR. (Mean ± SEM) 
D) Above: Bisulfite modified gDNA from differentiated (D) and not differentiated (ND) 
VSMCs, L6E9 myoblasts (Mb) and myotubes (Mt), and methylation control (Met) were used 
as template for bisulfite sequencing analysis. Second round PCR generated a single 312 bp 
product. N, negative control. , DNA-ladder. Below: 312 bp-PCR product and its position in 
the Mfn2 promoter (-315 to -4). The grey fragment of 211 pb (-262 to -52), corresponds to the 
sequencing result.  
E) Representative direct sequencing results showing 4 out of the 15 CpG sites studied. 
Original gDNA (-107 to -67) with the CpG sites indicated in bold, bisulfite modified gDNA, 
sequencing result of bisulfite modified unmethylated gDNA (in this case not differentiated 
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VSMCs) and methylation control were shown. : SssI methylated cytosine from the CpG 
motives.  
 
Figure 3. Functional analysis of the proximal human Mfn2 promoter.  
A) The region -229/+348 and deletions at 5’ of human Mfn2 were cloned in the promoterless 
pGL3 reporter vector and cotransfected with Renilla reporter plasmid in 10T1/2 cells. 
Transcriptional activity was normalized for the level of Renilla activity and expressed as fold 
activity of pGL3 promoterless vector.  
B) The two main transcription start sites (TSS2 and TSS5) were mutated in the construction -
229/+348-Luc as indicated (crossed) and cotransfected with Renilla reporter plasmid in 
10T1/2 cells. Transcriptional activity was normalized for the level of Renilla activity and 
expressed as fold activity of -229/+348-Luc wild type. (Mean ± S.E.M. of 3 experiments 
performed in triplicate;*, p< 0.001). 
 
 
Figure 4. Functional analysis of human Mfn2 promoter.  
A) -1982/+45-Luc and 5’ deletions, as indicated on the left panel, were cotransfected with 
Renilla reporter plasmid in 10T1/2 (□), and VSMCs (■). Cells were harvested 40 hours after 
transfection and luciferase activity was determined. Transcriptonal activity was normalized 
by Renilla and expressed as fold activity of pGL3 promoterless vector.  
B) The region -229/-54 was deleted in the construction -532/+45-Luc by restriction digestion. 
Each construct was cotransfected with Renilla reporter plasmid in 10T1/2 cells. 
Transcriptional activity was normalized by Renilla and expressed as fold activity of -
532/+45-Luc wild type vector. (Mean ± S.E.M. of 3 experiments performed in triplicate). 
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Figure 5. Mfn2 promoter is regulated by Sp1 transcription factor. 
A) The -1982/+45-Luc vector was cotransfected with GFP and Sp1 expression vectors in 
10T1/2 cells (□) or was cotransfected with Renilla in VSMCs (■). Transcriptional activity 
was normalized and expressed as fold activation of -1982/+45-Luc (basal). (Mean ± S.E.M. 
of 3 experiments performed in triplicate;*, p< 0.01). 
B) Chromatin immunoprecipitation of endogenous Sp1 in the Mfn2 promoter. In vivo cross-
linked chromatin from rat VSMCs or L6E9 cells was immunoprecipitated with anti-Sp1 or 
without antibody, followed by PCR amplification using specific primers for the Mfn2 
promoter, the exon 2 and an intergenic region ~10 kb upstream of the Mfn2 transcription start 
site. 
C) Apo E-KO mice were fed during 1 week with control chow (□) or atherogenic diet (■). 
Sp1 and Mfn2 mRNA from aorta were measured by real time-PCR and expressed relative to 
Cyp mRNA levels. (Mean ± S.E.M. 4 pools of each diet, *, p<0.05). 
D) Sp1 and Mfn2 mRNA expression from rat VSMCs cultured in 10% or 0.2% FBS during 
48h were determined by real-time PCR. (Mean ± S.E.M. of 3 experiments performed in 
triplicate;*, p< 0.05). 
 
Figure 6. Mfn2 promoter activity is abolished in response to Sp1 deficiency. 
A) Western blot of total extracts obtained from rat VSMCs and L6E9 cells transduced with 
lentiviral vectors encoding Sp1 shRNA (shSp1) or scramble control sequences (C). Sp1 and 
Tubulin proteins were detected using specific antibodies. n=3-5. 
B) Relative protein expression of  Sp1 from rat VSMCs and L6E9 cultures transduced with 
lentiviral vectors encoding Sp1 shRNA (shSp1) or scramble control sequences (C) (Mean ± 
S.E.M. of 3-5 experiments, *, p<0.05). 
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C) The -532/+45-pGL3 or -229/-54-pGL3 vectors were cotransfected with Renilla expression 
vector in L6E9 cells transduced with lentiviral vectors encoding Sp1 shRNA (shSp1) or 
control plasmid (C). Transcriptional activity was expressed as fold change of control. (Mean 
± S.E.M. of 3 experiments performed in triplicate;*, p< 0.01). 
D) The -532/+45-pGL3 or -229/-54-pGL3 vectors were cotransfected with Renilla expression 
vector in L6E9 cells. Four hours after transfection, cells were incubated with 300 nM WP631 
(WP631) or PBS (Basal) during 24h. Transcriptional activity was expressed as fold change of 
control. (Mean ± S.E.M. of 3 experiments performed in triplicate; *, p<0.01). 
E) VSMCs were treated with various concentrations of WP631 for 24 hours. Thereafter, total 
RNA was extracted, and Mfn2 and Cyclophilin A mRNA levels were analyzed by real time-
PCR. (Mean ± S.E.M. of 5 experiments, *, p<0.05). 
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-950 ttctcctgcctcttcctcccgagtgcactatcatgcctggctaatttttg 
                                                                                                             Myogenin 
-900 tatttttagtacagacggggtttcaccatgttggccaggctggtcttgaa 
-850 ctcccgatgcacccgcctcgccctcctaaaatgctggaattacaggcttg 
-800 agccaccgcgcccggtcgatatttttttttcctaaaaattgagatagttt 
                                                                            NFAT                    GATA-1 
-750 aacagccttttttgtcctaagtcttatagcgcatctccgtttgcactggc 
-700 tcaggactcgagagccacacgtggctagtgcctactgttctggcgcgctc 
-650 aggcttggagccttctctgcggaggccaagtcctgcaagggatctgtttg 
                                                                                                                          AP-1 
-600 ctgcggtttcctagtagtgtctgccgcatcactggggcccggtgatctgg 
-550 gtaaccatgtgagcttgggtaacctctcctctccctctcctgggactgct 
                                                    C/EBP                            NFκB 
-500 gtggacgttaaatacagcggtggatgttagagacgcagttcagtcactgg 
                                                                                                                  AP-1 
-450 cattgattcgccgttgttgctgctcttctttcctcaaaggcgactgaagg 
                                                                                 C/EBP 
-400 gcagcaggcccatgctcgcttctgtctgcccgatgagtcacttcacccta 
-350 ggcctggccctctagagaacactcctctaagattacagaatgcaaatctg 
                                                                                           C/EBP 
-300 gattccagagctggcagaggccccagggtcaggctctaggacaaccggcg 
-250 aaaaagcgggaacctctactccacgcccttggtttttcgccccttgacag 
                                                                         Sp1 
-200 cttgaggctccgccccgctttgccccgcccccccagctccggccgacgcc 
                                      Sp1                            Sp1 
-150 caccggaactacagcccccatgatgcagtgggagtccgagcctctgcgtc 
                                                                                                     Sp1 
-100 gtccgcttgggacgcgccggcggaggagtggcgcgcggaggagtggcgcg 
                                                                           Sp1                               Sp1 
 -50 ctgagacgccgctcgaagcgccgagtcgcggggcagcagaggcgtaagga 
  +1 gtaggcggggcgagccggctgggctcagggtccaccagctcacccgggtc 
 +51 gaggggcaatctgaggcgactggtgacgcgcttatccacttccctcctcc 
+101 cgcctccccccggggtggcgctcgctggtgacgtagtgagtgtgatggcc 
+151 gccgcgaggccgggaaggtgaaggtgagagggcgagcaagccggggtggc 
+201 ggggactggcccggcccggcccggcgagtcctgagcagctcggcgtgggc 
+251 cgacgggattctggggccacgggggtctgggatgcagtcaagcggggtcc 
B 
 
-950 cttggtagcagccatttatacctactgagccttttttgtgaccgccacta 
-900 ttagctctacttttagaagtaagaagaaacggggtggggggggcgattta 
                                                                                                   Sp1 
-850 attaagataatgtatttcatttagcccagtttatccaaagctataacaac 
               C/EBP    GATA-1                                                      GATA-1 
-800 acatcaatataaaattactaataaggtagtttgcatttctttttatatta 
                                                                                                             GATA-1 
-750 aacattggggcatttctcagtttgtagcagctgcatttcagggtctcagt 
-700 agctacaagtggctggtgggtgttactacagagcccaggcttggagccct 
                               AP-1                                                   NFκB  
-650 cccagcttggggtccaatgcagtatcccagttcttggaacaaaatgaggg 
-600 gccagtgaatggcatgtgaggttggataatcatgtcctgaatgtcctggg 
                                                                        C/EBP 
-550 actgagtgaaaattaaaaactgcatgttagatagccagtgcaatgactgt 
                        AP-1                                                                                     AP-1 
-500 cacctagtagctgcctgatgcgttgtggctgctgtttagttgcctcaaag 
                                                                              C/EBP 
-450 gcaactgaaggacaattacttcaccctaacggtctgtttgttccctttga 
                                 RORα  
-400 agacactcggattatgaaatgcgagtctggatttcaaaactgacaggtgt 
-350 tatacagggtcaaattctggagcagcaacaacaaaaaaggcgcaacaaca 
-300 aaaaaggcgcacgcaaacctctaatcggtacccttgtcgtgtcctgcccg 
-250 ctcccctccccgccgtccaccctctcccctcccccaacccccgtcccgtt 
                  Sp1                                                  Sp1                              Sp1 
-200 ctcccacccctccaacccctgcttgacagctcgaggctccgccctacccc 
                                                                                                             Sp1 
-150 accctgacggacgctgatccaaactacaactcccatgacgcgctgggagc 
                  Sp1 
-100 cccaccctacagcttacgtcatctgcacgagacacgggacggttaccagg 
                    Sp1 
 -50 cacgcgggggctccttttggagcgcggagttcctagacactgtggtatag 
                                  Sp1 
  +1 gagtggtaaggttgaggtgacagcgttcagaggccatcggctcgtccggg 
 +51 ctgcagcggggcgagtgacgagcgcagccccctcccctcccgcttctctc 
+101 ggtgtggcgccggctagtgacgtgttgggtgtgatggccgccgcgaggcc 
+151 gggaaggtgaaggtgagagggcgagcgcgccggggtggtggaaccggcag 
+201 gcccgggccgggagagtcctgagccacccggcttaggacgctgggcctct 
+251 ggggcctctgggcctcgggctcaggctcgggtcacacgggcgtttcccct 
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Supplementary Data 
 
Supplementary Methods 
 
Cell culture. Cells were cultured in a humidified atmosphere with 5% CO2 at 37 ºC. 
C3H10T1/2 cells were grown in DMEM supplemented with 10% FBS and 100 units/ml 
penicillin and 100 µg/ml streptomycin. Primary rat aorta VSMCs were prepared as previously 
described1 and were grown in DMEM-F12 (1:1) supplemented with 10% FBS, 2 mM 
glutamine, 0.25 µg/ml fungizone, 100 units/ml penicillin and 100 µg/ml streptomycin and 25 
mM Hepes. Preconfluent VSMCs were induced to differentiate by incubating them in 
medium containing 0.5% FBS during 48h. The L6E9 rat skeletal muscle cell line was cultured 
in DMEM containing 10% FBS, 100 units/ml penicillin G and 100 µg/ml streptomycin and 25 
mM Hepes (pH 7.4) (Growth Medium). Pre-confluent myoblasts (80-90%) were induced to 
differentiate by lowering FBS to a final concentration of 2% (vol/vol) (Differentiation 
Medium). Cells were completely differentiated after 4 days in this medium. INS-1 rat 
insulinoma cell line was cultured in RPMI 1640 supplemented with 10% FBS, 10 mM Hepes 
(pH 7.4), 1 mM sodium piruvate, 50 µM beta-mercaptoethanol, 2 mM glutamine, 100 
units/ml penicillin G and 100 µg/ml streptomycin. H4IIE rat hepatoma cell line was cultured 
in DMEM supplemented with 10% FBS, 100 units/ml penicillin G and 100 µg/ml 
streptomycin. FAO rat hepatoma cell line was cultured in F-12 Coon´s Modification (Sigma) 
supplemented with 10% FBS, 2 mM glutamine, 100 units/ml penicillin G and 100 µg/ml 
streptomycin. 
 
In vivo studies. Four-month-old Apo E-KO mice (C57BL/6J, Charles River) were fed either 
control chow or an atherogenic (ATG) diet for 1 week (10.8% total fat, 0.75% cholesterol, 
S8492-E010, Ssniff, Germany). After sacrifice, the aorta was collected (pooled from 1 male 
and one female), immediately snap-frozen and stored at -80ºC. For some other purposes, 
tissues from adult male Wistar rats (Harlan Laboratories, Spain) were obtained, immediately 
snap-frozen and stored at -80ºC. Ascending aorta and aortic arch from young (2 months) and 
old (24 months) male rats were collected and frozen immediately in liquid nitrogen. Aortic 
tissues were pooled (each pool contained the ascending aorta and the aortic arch from the 
same rat). All experiments were conducted in accordance with approved institutional 
operating protocols and the Directive 2010/63/EU of the European Parliament. 
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Rapid amplification of cDNA ends (RACE). The TSSs of human Mfn2 in skeletal muscle 
were identified using the FirstChoice® RACE-Ready cDNA (Ambion) following the 
manufacturer’s protocol. The 5’ end of human Mfn2 cDNA was amplified using a standard 
nested PCR protocol2. To avoid the amplification of partially degraded mRNA an adapter 
linked only to mRNA with CAP (from human skeletal muscle) was used. Primers were 
designed to match sequences in exon 2: 5’-agattctgagttctcttctgtccta-3’ and nested 5’-
ttgattgactgtgttgactccaccag-3’. The resulting PCR products were purified, cloned in pGEM-T 
easy (Promega) and sequenced. 
 
Construction of luciferase reporter vectors. The pGL3-promoterless vector was generated 
by excision of the SV40 promoter by digestion with BglIII/HindIII. The -1982/+45 Mfn2 
promoter fragment was cloned into the SacI/SmaI sites of pGL3-promoterless vector 
(Promega). The subsequent 5’ deletion constructs were produced by double digestion and 
religation. Forward primer 5'-cagggtcaggctctaggaca-3’and reverse primer 5'-
gcttgactgcatcccagac-3' were used to generate the human -276/+275 Mfn2 promoter region. 
The amplified DNA fragment was digested with SacI/NcoI and cloned into SacI/NcoI sites of 
pGL3-promoterless vector (Promega). The subsequent 5’ deletion constructs were produced 
by double digestion and religation. The construct -532/+45∆-229/-54-pGL3 was produced by 
double digestion BssHII/BstXI of the construct -532/+45-pGL3 and subsequent religation. 
 
Transfection and luciferase assays. VSMCs, C3H10T1/2 or L6E9 cells were seeded into 24-
well plates at a density of 25,000 cells per well, 24 hours before transfection. pGL3 reporter 
constructs (250 ng) and 20 ng of Renilla luciferase (used as an internal control for transfection 
efficiency) were transfected using FuGENE 6 (Roche), following the manufacturer’s protocol.  
At 40 hours post-transfeccion, luciferase and Renilla activity was measured using the Dual 
Luciferase Reporter Assay System (Promega), following the manufacturer’s protocol. For Sp1 
transfections, 250 ng of the expression plasmid3 and 50 ng of GFP in C3H10T1/2 cells or 40 
ng of Renilla luciferase in VSMCs, together with 250 ng of pGL3 reporter construct, were 
transfected. GFP was measured by flow cytometry. Expression of reporter genes was 
normalized to GFP measured by flow cytometry or Renilla activity. 
 
RNA purification and measurement of mRNA expression. RNA was extracted with 
TRIZOL Reagent (GibcoBRL, Invitrogen) according to manufacturer’s instructions. The 
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Invitrogen’s SuperScrip™ II Reverse Transcriptase was used to obtain cDNA from RNA. 
One or two µg of RNA was used for retro-transcription. Real time-PCR was performed with 
specific primers and using SYBR-Green PCR Master Mix (Applied Biosystems) according to 
manufacturer’s instructions. In all cases, a single PCR product was detected. Results were 
expressed as number of mRNA copies relative to Cyp gene expression. For the Apo E-KO 
mice experiment, fold change values were calculated as the ratio of the ∆Ct sample averages. 
Relative quantification (RQ) is defined as 2- ∆∆Ct. For each gene, results in ATG diet are 
normalized versus control diet (RQ=1). PRIMERS:  rat Cyp (rCyp-f ctttgacttgcgggcattttac ; 
rCyp-r aagaacttcagtgagagcagagattacagg), rat ARP (rARP-f gagccagcgaagccacact ; rARP-r 
gatcagcccgaaggagaagg), rat Mfn2 (rMfn2-f gacctgcaccgagaagagaca ; rMfn2-r 
ctgcagggggtagggagtaac), rat Sp1 (rSp1-f cggcaaagtatatggcaaaacct ; rSp1-r 
agtaaagcgcttcccacagtatga), mouse Cyp (mCyp-f caaatgctggaccaaacacaaac ; mCyp-r 
tgccatccagccattcagtc), mouse Mfn2 (mMfn2-f gtaagggctcggagaaggtatgtg ; mMfn2-r 
tggcaagaagggaggcaagtc), mouse Sp1 (mSp1-f catgccaggcctccagacc ; mSp1-r 
caccagatccatgaagaccaagtt). 
 
Bisulfite modification of genomic DNA, PCR and sequencing. Genomic DNA (gDNA) 
purification was performed using the traditional phenol/chlorophorm/isoamyl alcohol method. 
gDNA isolated from not differentiated and differentiated rat VSMCs and L6E9 cell line as 
well as from tumoral cell lines and rat tissues were modified with the EzWay DNA 
Methylation Detection Kit (Koma Biotech) according to manufacturer’s protocol. Briefly, 1 
µg gDNA was treated with sodium bisulfite to modify unmethylated cytosine residues to 
uracil, while 5-methyl cytosines remain unaltered. Modified gDNA was purified using the 
Qiaquik PCR Purification Kit (Qiagen). A 519 bp region spanning from -489 to +29 of the 
Mfn2 gene was hot start PCR amplified using forward degenerated 5'-aygtaagtttggattt-3' and 
reverse 5'-cctctcaccttcacct-3' primers that recognized bisulfite modified DNA. PCR conditions 
were: 10 min at 94°C, (30 s at 94°C, 35 s at 52°C, and 40 s at 72°C) for 40 cycles, and 5 min 
at 72°C. Then, a 1/10 dilution of the first round PCR products was subjected to a nested 
second round hot start PCR amplification using forward degenerated 5'-tgatagttygaggtttygt-3' 
and reverse 5'-accatcacacccaac-3' primers, yielding a product of 312 pb (-315 to –4). Second 
round PCR conditions were: 10 min at 94°C, (30 s at 94°C, 35 s at 56°C, and 40 s at 72°C) for 
40 cycles, and 5 min at 72°C. Not bisulfite treated genomic DNA and bisulfite-treated in vitro 
SssI methylated rat DNA were used as controls. Water without addition of DNA served as 
negative control. The last PCR products (312 bp) were run on 2% agarose gels and stained 
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with ethidium bromide. 1 Kb Plus-DNA-ladder (Gibco) was used. The bands were gel 
purified using the illustra GFX PCR DNA and Gel Band Purification Kit (Amersham), and 
sequenced with the same second round PCR primers using the ABI BigDye V3.1 sequencing 
kit (Applied Biosystems) and an automated DNA sequencer (3730XL Applied Biosystems). 
Therefore, we amplified a bisulfite treated DNA fragment containing 22 CpG dinucleotides, 
and were able to analyze 15 individual CpG sites. 
 
Chromatin immunoprecipitation. Chromatin was isolated from rat L6E9 cells and VSMCs 
grown in high (10% FBS) or low serum (0.2% FBS during 48h) conditions. Briefly, cells 
were cross-linked using a final concentration of 1% formaldehyde for 10 min. The cross-
linking reaction was stopped by the addition of 1.25 M glycine. Cross-linked cells were 
washed in 1x PBS with 0.5 mM PMSF and collected. Cells were resuspended in cell lysis 
buffer (10 mM EDTA, 0.5 mM EGTA, 10 mM Hepes at pH 6.5, 0.25% TX-100 and protease 
inhibitor cocktail). Nuclei were then lysed in 50 mM Tris-HCl (pH 8.1), 10 mM EDTA, 1% 
SDS and protease inhibitor cocktail (Roche). Isolated chromatin was then sonicated to an 
average fragment size of 400 to 500 bp. Precleared chromatin was then immunoprecipitated 
with antibody against Sp1 (sc-59 X, Santa Cruz Biotech) and pre-blocked Protein A beads 
(Sigma). Immunoprecipitation with no antibody was performed as a control for nonspecific 
interaction of DNA. Samples were washed in buffer 1 (0.1% SDS, 1% TX-100, 2 mM EDTA, 
20 mM Tris-HCl at pH 8.1 and 150 mM NaCl), followed by another wash using buffer 2 
(buffer 1 with 500 mM NaCl). Following this, samples were washed with buffer 3 (10 mM 
Tris-HCl at pH 8, 0.25 M LiCl, 1% NP-40, 1% deoxycholate and 1 mM EDTA) and then 1x 
TE (pH 8). Precipitated chromatin was then subjected to reverse cross-link overnight and 
purified by phenol/chloroform extraction. Input and immunoprecipitated DNA were subjected 
to PCR analysis with primers flanking the Sp1 site on the Mfn2 promoter. The coding region 
2 and an intergenic region ~10 kb upstream of the Mfn2 transcription start site were also 
amplified as controls for nonspecific binding of genomic DNA. The following primers were 
used: for the Mfn2 promoter (forward: 5’-GCCTCTGAACACCGTCACTT-3’ and reverse: 
5’-CGCACCCTTATCGTTTTTGT-3’), for the Mfn2 exon 2 (forward: 5’-
CACCATCAGTAGCCAATCTGGA-3’ and reverse: 5’-TTCACAGGTTGGGCATCATG-
3’) and for the intergenic region (forward: 5’-GCCTTGGGATGATCCTCCTT-3’ and reverse 
5’-CCCTAACTAAAGCAAACAGGCATG-3’). 
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Western blot. Cells were collected in ice-cold PBS 1X and homogenized using a dounce 
homogenizer in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 2 mM 
EDTA, 2 mM sodium ortovanadate, 50 mM NaF, 20 mM sodium pyrophosphate and protease 
inhibitors cocktail tablet, Roche). Fifteen micrograms proteins from each sample were 
resolved in 7.5% acrylamide gels for SDS-PAGE and transferred to Immobilon membranes 
(Millipore, Bedford, USA). The following antibodies were used: Sp1 (1:1000, Santa Cruz), 
and tubulin (1:8000, Sigma). Peroxidase-conjugated anti-mouse or anti-rabbit 
immunoglobulins (1:10000) were used as secondary antibodies. 
 
shRNA. For Sp1 expression silencing, 5 different mouse shRNA sequences (MISSION 
shRNA clones, Sigma-Aldrich) included in shRNA lentiviral plasmids (pLKO.1-puro) were 
used. Clone ID, target sequence: TRCN0000071603, 
CCGGGCAGCAGTAATACCACCCTAACTCGAGTTAGGGTGGTATTACTGCTGCTTT
TTG; TRCN0000071604, 
CCGGCCCAACTTACAGAACCAGCAACTCGAGTTGCTGGTTCTGTAAGTTGGGTTT
TTG; TRCN0000071605, 
CCGGGCAGGATGGTTCTGGTCAAATCTCGAGATTTGACCAGAACCATCCTGCTTT
TTG; TRCN0000071606 
CCGGCCTTCACAACTCAAGCTATTTCTCGAGAAATAGCTTGAGTTGTGAAGGTTTT
TG; and TRCN0000071607 
CCGGCCAATGCCAATAGTTATTCAACTCGAGTTGAATAACTATTGGCATTGGTTTT
TG. 
shRNA lentiviral non-target control plasmid (MISSION® Non-Target shRNA Control 
Transduction Particles, Sigma-Aldrich) was used as a control. 
 
Lentivirus packing and infection. Lentiviruses encoding scrambled and Sp1 shRNA were 
produced by triple transient transfection of HEK293T 4. Briefly, the lentivirus expression 
plasmid (pLKO.1-puro-shSp1 or control vector), together with pCMV-dR8,74 (helper 
packaging construct) and pMD2.G (vector encoding for envelope protein) plasmids kindly 
provided by Dr. D. Trono from the Ecole Polytechnique Federale de Lausanne (Switzerland), 
were transiently co-transfected into HEK293T cells in the presence of 0.05 mg/ml PEI pH7 
(Linear MW 25.000, Polyscience, Inc.) and 150 mM NaCl. Lentivirus was harvested at 48 
and 72 h posttransfection, centrifuged to get rid of cell debris, and then filtered through 0.45 
cellulose acetate filters followed by ultracentrifugation.  
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For lentivirus infection, rVSMC and L6E9 cells were plated at 10.000 cells/ml in 6 well 
plates, infected with 1:10 of total obtained Sp1-shRNA lentivirus or control lentivirus and 
incubated at 33ºC. Twenty four hours after infection, virus containing media was removed, 
standard culture media was added and incubation continued at 37ºC. Puromycin selection (6 
ug/ul for rVSMC and 3 ug/ul for L6E9) was performed four days after infection and resistant 
cells were amplified for 1-2 additional passages. At 70–80% confluence cells were harvested 
and lysed. 
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Legends to Supplementary Figures 
 
Supplementary Figure 1. Nucleotide sequence of the 5’ region of rat Mfn2.  
+1 represents the transcription start site reported in NCBI (NM 130894 for rat sequence) and 
the first exon is shaded. Putative transcription-regulatory motifs are in bold and underlined. 
Functional estrogen-related receptor-α (ERRα)-binding element is shown inside a rectangle. 
 
Supplementary Figure 2. Human Mfn2 5’-flanking region is located in a CpG island. 
Position and characteristics of the CpG island associated with the Mfn2 promoter region, 
showing observed versus expected CpG, (G+C) content and the location of the CpG island.  
 
Supplementary Figure 3. Determination of human Mfn2 transcription start sites in 
human skeletal muscle.  
A) 5’-RACE analysis of human Mfn2 mRNA from skeletal muscle. The PCR products 
(second round of amplification) were resolved on agarose gel, at least three bands were 
visualized by ethidium bromide staining (arrows); C is the negative control. The PCR product 
was cloned and 22 clones were sequenced.   
B) Six transcription start sites (TSS) were identified (TSS1 2 clones; TSS2 8 clones; TSS3 1 
clone; TSS4 2 clones; TSS5 8 clones; TSS6 1 clone), three of them with homology with the 
consensus Inr element (shaded). 
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